[HTML][HTML] Real-word effectiveness of global COVID-19 vaccines against SARS-CoV-2 variants: a systematic review and meta-analysis

K Wang, L Wang, M Li, B Xie, L He, M Wang… - Frontiers in …, 2022 - frontiersin.org
Background Currently, promoted vaccinations against SARS-CoV-2 are being given out
globally. However, the occurrence of numerous COVID-19 variants has hindered the goal of …

[HTML][HTML] SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

JS Turner, JA O'Halloran, E Kalaidina, W Kim… - Nature, 2021 - nature.com
Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …

[HTML][HTML] In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

RE Chen, ES Winkler, JB Case, ID Aziati, TL Bricker… - Nature, 2021 - nature.com
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

[HTML][HTML] A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

LA VanBlargan, LJ Adams, Z Liu, RE Chen, P Gilchuk… - Immunity, 2021 - cell.com
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Beyond COVID‐19 and lessons learned in the United States

R Gammon, LM Katz, D Strauss, K Rowe… - Transfusion …, 2023 - Wiley Online Library
The COVID‐19 pandemic severely tested the resilience of the US blood supply with wild
fluctuations in blood donation and utilisation rates as community donation opportunities …

[HTML][HTML] Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

AA Gorchakov, SV Kulemzin, SV Guselnikov… - Cell Discovery, 2021 - nature.com
In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

Cross-neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike

S Changrob, Y Fu, JJ Guthmiller, PJ Halfmann, L Li… - Mbio, 2021 - Am Soc Microbiol
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

Structure of a vaccine-induced, germline-encoded human antibody defines a neutralizing epitope on the SARS-CoV-2 spike N-terminal domain

CG Altomare, DC Adelsberg, JM Carreno, IA Sapse… - Mbio, 2022 - Am Soc Microbiol
Structural characterization of infection-and vaccination-elicited antibodies in complex with
antigen provides insight into the evolutionary arms race between the host and the pathogen …

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

T Ozawa, H Tani, Y Anraku, S Kita, E Igarashi, Y Saga… - MAbs, 2022 - Taylor & Francis
Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for
therapies. However, the effectiveness of many antibodies has been reduced against recently …

[HTML][HTML] XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes …

B Vanhove, S Marot, RT So, B Gaborit… - Frontiers in …, 2021 - frontiersin.org
Amino acid substitutions and deletions in the Spike protein of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal …